Regorafenib-induced hand-foot skin reaction in an adolescent

Last Updated: Wednesday, May 21, 2025

In this case report, an adolescent with metastatic osteosarcoma developed severe, grade 3 regorafenib-induced hand-foot skin reaction (HFSR). This HFSR limited her ability to ambulate. The case demonstrates management involving supportive measures and temporary discontinuation of regorafenib, highlighting the absence of standard pediatric guidelines.

Pediatric Dermatology

Surgical Case Reports

Neoadjuvant chemotherapy followed by laparoscopic and endoscopic cooperative surgery for locally advanced duodenal gastrointestinal stromal tumor: A case report

Journal of the College of Physicians and Surgeons—Pakistan

Predictive significance of changes in haemoglobin level following imatinib treatment in patients with advanced gastrointestinal stromal tumour

European Journal of Clinical Pharmacology

Influence of genetic variants of imatinib on pharmacokinetics and recurrence-free survival in postoperative patients with gastrointestinal stromal tumor

Pathology, Research and Practice

An interpretable machine learning framework for automated mitosis detection in gastrointestinal stromal tumors

Molecular Therapy Oncology

Targeting MITF as a tyrosine-kinase-inhibitor-independent strategy for treating GIST

Radiology Case Reports

Gastrointestinal stromal tumor of the rectum: A case report with emphasis on MRI-pathologic correlation

World Journal of Gastrointestinal Oncology

Utility of inflammatory markers as predictors of recurrence in gastrointestinal stromal tumors: Insights from a nomogram-based approach

Surgical Endoscopy

A novel prognostic system for locally advanced gastrointestinal stromal tumors after neoadjuvant imatinib therapy based on the metro-ticket paradigm: a retrospective dual-center study

Langenbeck's Archives of Surgery

Partial resection of rectum for rectal GIST by posterior approach

Clinical and Translational Medicine

Beta-elemene promotes ferroptosis to improve the sensitivity of imatinib in gastrointestinal stromal tumours by targeting N6AMT1

Gastrointestinal Stromal Tumor Resource Center